#chinapharmaceuticalmarket — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #chinapharmaceuticalmarket, aggregated by home.social.
-
Novo Nordisk will lose patent protection for semaglutide in China next year, opening the market to up to 20 biosimilar and generic competitors amid intensifying competition.
#YonhapInfomax #NovoNordisk #Semaglutide #PatentExpiry #ChinaPharmaceuticalMarket #GLP1Drugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65853 -
Novo Nordisk will lose patent protection for semaglutide in China next year, opening the market to up to 20 biosimilar and generic competitors amid intensifying competition.
#YonhapInfomax #NovoNordisk #Semaglutide #PatentExpiry #ChinaPharmaceuticalMarket #GLP1Drugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65853 -
Novo Nordisk will lose patent protection for semaglutide in China next year, opening the market to up to 20 biosimilar and generic competitors amid intensifying competition.
#YonhapInfomax #NovoNordisk #Semaglutide #PatentExpiry #ChinaPharmaceuticalMarket #GLP1Drugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65853 -
Novo Nordisk will lose patent protection for semaglutide in China next year, opening the market to up to 20 biosimilar and generic competitors amid intensifying competition.
#YonhapInfomax #NovoNordisk #Semaglutide #PatentExpiry #ChinaPharmaceuticalMarket #GLP1Drugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65853